The FlexShares Quality Dividend Index Fund (QDF) promises steady income through quality screens, but its substantial allocation to technology stocks—making up one-third of the portfolio—may reshape risk expectations for investors, particularly retirees seeking stability.
The biotech company Grail has formally submitted its Galleri test for FDA premarket approval, a critical step that could unlock widespread insurance reimbursement and integrate the multi-cancer screening tool into mainstream preventive care.
Wall Street's top analysts made waves Monday with revised ratings on key stocks, highlighting a growing divergence in tech and retail outlooks as earnings season approaches.
Despite a steep share price decline, UiPath is carving out a dominant position in the burgeoning 'agentic AI' market, which promises to automate complex workflows. Strong customer loyalty and improving profitability suggest the automation software provider may be undervalued ahead of a projected industry explosion.
Piper Sandler and Barclays have raised price targets for CytomX Therapeutics (CTMX), citing promising early-phase data for its experimental colorectal cancer therapy. Updated results from a larger patient cohort are expected this quarter.
Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
Wells Fargo boosts its price target for Taysha Gene Therapies (TSHA), citing strong progress in its pivotal Rett syndrome gene therapy program. The company has dosed the first patient in a key trial phase and received FDA alignment on its regulatory pathway.
Clear Street downgrades Janux Therapeutics (JANX) to Hold, slashing its price target amid concerns over a lack of durability data for its lead candidate JANX007 and rising competitive pressures, despite a recent major collaboration deal with Bristol Myers Squibb.
Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.
CFOs are no longer just funders of AI experiments but central architects of its enterprise-wide deployment, navigating a critical shift from promise to production.
Three decades after its birth, New York's Silicon Alley has matured into a distinct tech ecosystem, anchored by profitability, cross-industry ties, and resilience through multiple booms and busts.
Despite shrinking margins on new vehicle sales, Group 1 Automotive posted its highest-ever annual revenue, powered by robust growth in its service departments and finance operations. The auto retailer credits strategic investments in technician retention and a shift toward higher-margin repair work.
The death of Jose 'Gonzalito' Sanchez, second-in-command of Colombia's largest criminal syndicate, in a boating accident raises immediate questions about the stability of ongoing government negotiations aimed at ending decades of conflict.
Seventeen-year-old Hailey Buzbee vanished after leaving her Vermillion home in early January. Authorities now believe she is deceased and have arrested a man she met through online gaming, though murder charges have not yet been filed.
The White House has confirmed the launch of a major strategic initiative to stockpile rare earth elements, aiming to reduce American dependence on China for the critical minerals used in defense tech and consumer electronics.
As Pzena Investment Management's latest commentary highlights a challenging quarter for value strategies, one of its holdings, freight giant Knight-Swift, comes into focus. We examine the investment case for KNX amidst shifting economic currents and a market dominated by AI hype.
The $12 trillion asset manager founded by Jack Bogle announced another round of expense reductions across 53 funds, saving investors an estimated $600 million over two years and reinforcing its half-century mission of driving down costs for the everyday investor.
The Invesco NASDAQ-100 Equal Weight ETF (QQEW) has executed a dramatic portfolio shift, halving its holdings from 101 to 50 companies. This strategic pivot from pure equal-weighting to a quality-filtered approach aims to mitigate the risks of extreme concentration in the tech-heavy index while maintaining its core diversification ethos.
As housing costs squeeze employees nationwide, a new wave of benefits is emerging. Fintech startup Oro has raised $3 million to help employers offer housing assistance, signaling a major shift in corporate wellness strategies.
Hilton is deepening its investment in Utah's premier Deer Valley Resort with a new Waldorf Astoria hotel and branded residences, signaling a major push into high-end, experience-driven mountain hospitality as competition for affluent travelers intensifies.
